Epidemiology of the antiphospholipid antibody syndrome

Journal of Autoimmunity

Volumn 15, Issue 2, 2000, Pages 145-151

  Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti oxidized LDL; Anticardiolipin; Epidemiology; Lupus anticoagulant; Prevalence

Indexed keywords

CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; PREGNANCY COMPLICATION; PREVALENCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VEIN THROMBOSIS;

EID: 0033834033     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0409     Document Type: Conference Paper

References (63)

1. The frequency of lupus anticoagulant in systemic lupus erythematosus: A study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody
2. Anticardiolipin response in acute infections
3. Criteria for the diagnosis of lupus anticoagulants: An update
4. Definition of normal autoantibody levels in an apparently healthy population
5. Neurological disease associated with antiphospholipid antibodies
6. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies
7. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population
8. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study
9. Anticardiolipin antibodies in unselected pregnant women in relationship to fetal outcome
10. Antiphospholipid antibodies in pregnancy: Prevalence and clinical associations
11. Anticardiolipin antibodies in ischaemic heart disease: Marker or myth?
12. Prevalence and disease associations of certain autoantibodies in elderly patients
13. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population
14. Anticardiolipin antibody associated ischaemic strokes in elderly patients without Systemic lupus erythematosus
15. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: Prospective analysis of a series of 100 patients
16. Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant
17. Outcome of pregnancy in patients with systemic lupus erythematosus: A prospective study
18. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients
19. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic upus erythematosus: A prospective analysis of 500 consecutive patients
20. Antiphospholipid antibodies in the connective tissue diseases: Their relation to the antiphospholipid syndrome and Forme Fruste Disease
21. SLE: A rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up
22. Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus
23. Longitudinal survey of anticardiolipin antibodies in systemic lupus erythematosus
24. Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus
25. Single anticardiolipin measurement in the routine management of patients with systemic lupus erythematosus
26. Clinical and management aspects of the antiphospholipid syndrome
27. Antiphospholipid antibodies, anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders
28. Antiphospholipid antibodies and venous thrombosis (VT) in SLE
29. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
30. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy
31. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism - Results of the Spanish Multicentric Study on Thrombophilia (EMET-Study)
32. Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis
33. Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis
34. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment
35. Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: Prevalence and association with recurrent thromboembolism
36. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - A meta-analysis
37. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - A nested case-control study
38. Hypercoagulable states in primary upper-extremity deep vein thrombosis
39. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men
40. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies
41. Cerebral infarction associated with lupus anticoagulants - Preliminary report
42. Etiology, prognosis, and hemostatic function after cerebral infarction in young adults
43. Antiphospholipid antibodies and cerebral ischemia in young people
44. Anticardiolipin antibodies, a disease marker for ischemic cerebrovascular events in a younger patient population?
45. Cardiolipin antibodies and lupus anticoagulant in young patients with a cerebrovascular accident in the past
46. Lupus anticoagulant and the fibrinolytic system in young patients with stroke
47. Factors that predict antiphospholipid immunoreactivity in young people with transient focal neurological events
48. Anticardiolipin antibodies: A study of frequency in TIA and stroke
49. Anticardiolipin antibodies and cerebral infarction
50. Clinical, radiological, and pathological aspects of cerebrovascular disease associated with antiphospholipid antibodies
51. The frequency of phospholipid antibodies in an unselected stroke population
52. Anticardiolipin antibodies are an independent risk factor for ischemic stroke
53. Importance of serum anticardiolipin antibody levels in coronary heart disease
54. Antibody against oxidized low-density lipoprotein predicting myocardial infarction
55. Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin
56. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss
57. Anti-cardiolipin antibodies and pre-eclampsia
58. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience
59. Autoantibodies and pregnancy loss
60. Lack of association between antiphospholipid antibodies and first-trimester spontaneous abortion: Prospective study of pregnancies detected within 21 days of conception
61. Anti-beta 2-glycoprotein I antibodies: A useful marker for the antiphospholipid syndrome
62. Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: A prospective study in low-risk pregnancy
63. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population